EU Pharmacovigilance Strategy: Public consultation on draft legislative proposals

EUDG Enterprise and Industry wishes to consult stakeholders on legislative proposals to strengthen and rationalise the EU system of pharmacovigilance. The Commission services conducted a previous consultation, between 16 March 2006 and 12 May 2006, which sought stakeholders' views on the strengths and weaknesses of the current EU system of pharmacovigilance and how the system could be strengthened. The web-based consultation was supplemented by public workshops in April 2006, as well as, meetings with specific stakeholder groups. The consultation results were made public in February 2007 and at the same time, in response to the consultation outcome, Vice- President Verheugen announced its "Strategy to Better Protect Public Health by Strengthening and Rationalising EU Pharmacovigilance". The Strategy has two parts: 1. better implementation of the current framework and, 2. proposals for change to the legal framework. Details of both the 2006 consultation and the Strategy are available on the Commission's website.

This public consultation specifically addresses part 2 of the strategy, the proposals for changes to the legal framework. This consultation paper is organised in the following sections:

  • Section 1 introduces the consultation, explains how and by when to submit consultation responses and explains the next steps.
  • Section 2 provides a brief orientation on pharmacovigilance and the background to the strategy.
  • Section 3 presents the legislative strategy and the key proposals for legislative change.
  • Section 4 presents detailed proposals to change EU legal texts.
The public consultation is open from 4 December 2007 to 1 February 2008. Stakeholders may wish to comment on the key proposals presented in Section 3 or may prefer to comment on the detailed proposals to change EU legal texts presented in Section 4. All comments should be sent electronically to Dr Peter Arlett by 1 February 2008.

For further information, download PUBLIC CONSULTATION ON LEGISLATIVE PROPOSALS document (.pdf).

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...